Literature DB >> 9352216

Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

D E Gomez1, D F Alonso, H Yoshiji, U P Thorgeirsson.   

Abstract

Four members of the tissue inhibitor of metalloproteinases (TIMP) family have been characterized so far, designated as TIMP-1, TIMP-2, TIMP-3, and TIMP-4. TIMP-1 and TIMP-2 are capable of inhibiting the activities of all known matrix metalloproteinases (MMPs) and as such play a key role in maintaining the balance between extracellular matrix (ECM) deposition and degradation in different physiological processes. Accelerated breakdown of ECM occurs in various pathological processes, including inflammation, chronic degenerative diseases and tumor invasion. TIMP-1 and TIMP-2 can inhibit tumor growth, invasion, and metastasis in experimental models which has been associated with their MMP inhibitory activity. Recent developments in TIMP research suggest that TIMP-1 and TIMP-2 are multifunctional proteins with diverse actions. Both inhibitors exhibit growth factor-like activity and can inhibit angiogenesis. Structure-function studies have separated the MMP inhibitory activity of TIMP-1 from its growth promoting effect. TIMP-1 has also been implicated in gonadal steroidogenesis and as a cellular elongation factor. TIMP-3 is the only member of the TIMP family which is found exclusively in the extracellular matrix (ECM). It is regulated in a cell cycle-dependent fashion in certain cell types and may serve as a marker for terminal differentiation. The most recently discovered TIMP, TIMP-4, may function in a tissue-specific fashion in extracellular matrix hemostasis. The main aim of this article is to review recent literature on TIMPs with special emphasis on their biological activities and the possibility that they may have paradoxical roles in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352216

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  294 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 3.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 4.  That impish TIMP: the tissue inhibitor of metalloproteinases-3.

Authors:  J F Woessner
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

5.  Matrix metalloproteinases in gastrointestinal cancer.

Authors:  P D Brown
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

6.  The effect of raloxifene, a SERM, on extracellular matrix protein expression of pelvic fibroblasts.

Authors:  Jung Han Lee; Yan Wen; Mary Lake Polan; Bertha Chen
Journal:  Int Urogynecol J       Date:  2011-09-21       Impact factor: 2.894

Review 7.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

8.  Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection.

Authors:  Jiehao Zhou; Stephen A Stohlman; Roscoe Atkinson; David R Hinton; Norman W Marten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 9.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

10.  The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells.

Authors:  Ase Bratland; Erlend Ragnhildstveit; Kristin Bjørnland; Kristin Andersen; Gunhild Mari Maelandsmo; Oystein Fodstad; Fahri Saatcioglu; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.